US Patent 7201905 Bi-functional cancer treatment agents
All edits
Edits on 6 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Thomas E. Wagner0
Wen Y. Chen0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+422 characters)
Article
Patent abstract
A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.
Edits on 16 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07201905 Bi-functional cancer treatment agents US Patent 7201905 Bi-functional cancer treatment agents
Infobox
Patent Number
07201905
Patent Number
7201905
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 20 Nov, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 07201905 Bi-functional cancer treatment agents
Infobox
Is a
Patent jurisdiction
Patent number
07201905
Date of patent
April 10, 2007
Patent application number
09815306
Date Filed
March 23, 2001
Patent primary examiner
Find more entities like US Patent 7201905 Bi-functional cancer treatment agents
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
